These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 9918213)

  • 21. High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer.
    Grignon DJ; Sakr W; Toth M; Ravery V; Angulo J; Shamsa F; Pontes JE; Crissman JC; Fridman R
    Cancer Res; 1996 Apr; 56(7):1654-9. PubMed ID: 8603416
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased plasma levels of urokinase plasminogen activator and matrix metalloproteinase-9 in nonsmall cell lung cancer patients.
    Yang SF; Hsieh YS; Lin CL; Hsu NY; Chiou HL; Chou FP; Chu SC
    Clin Chim Acta; 2005 Apr; 354(1-2):91-9. PubMed ID: 15748604
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Matrix metalloproteinases and their inhibitors.
    Kugler A
    Anticancer Res; 1999; 19(2C):1589-92. PubMed ID: 10365151
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer.
    Cox G; Jones JL; O'Byrne KJ
    Clin Cancer Res; 2000 Jun; 6(6):2349-55. PubMed ID: 10873086
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elevated serum levels of type I collagen degradation marker ICTP and tissue inhibitor of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer.
    Ylisirniö S; Höyhtyä M; Mäkitaro R; Pääakkö P; Risteli J; Kinnula VL; Turpeenniemi-Hujanen T; Jukkola A
    Clin Cancer Res; 2001 Jun; 7(6):1633-7. PubMed ID: 11410500
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Assay of matrix metalloproteinase levels and their endogenous inhibitors in patients with laryngeal carcinoma].
    Klisho EV; Savenkova OV; Kondakova IV; Perel'muter VM; Choĭnzonov EL; Shishkin DA
    Vopr Onkol; 2007; 53(1):26-31. PubMed ID: 17649730
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activation of pro-MMP-2 mediated by MT1-MMP in human salivary gland carcinomas: possible regulation of pro-MMP-2 activation by TIMP-2.
    Kayano K; Shimada T; Shinomiya T; Nakai S; Hisa Y; Aoki T; Seiki M; Okada Y
    J Pathol; 2004 Apr; 202(4):403-11. PubMed ID: 15095267
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas.
    Jones JL; Glynn P; Walker RA
    J Pathol; 1999 Oct; 189(2):161-8. PubMed ID: 10547569
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of matrix metalloproteinase-9 in the basement membrane destruction of superficial urothelial carcinomas.
    Ozdemir E; Kakehi Y; Okuno H; Yoshida O
    J Urol; 1999 Apr; 161(4):1359-63. PubMed ID: 10081908
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinase in uterine endometrial carcinoma and a correlation between expression of matrix metalloproteinase-7 and prognosis.
    Misugi F; Sumi T; Okamoto E; Nobeyama H; Hattori K; Yoshida H; Matsumoto Y; Yasui T; Honda K; Ishiko O
    Int J Mol Med; 2005 Oct; 16(4):541-6. PubMed ID: 16142384
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
    Sakata K; Shigemasa K; Nagai N; Ohama K
    Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Significance of matrix metalloproteinases and tissue inhibitors of metalloproteinase expression in the recurrence of superficial transitional cell carcinoma of the bladder.
    Hara I; Miyake H; Hara S; Arakawa S; Kamidono S
    J Urol; 2001 May; 165(5):1769-72. PubMed ID: 11342973
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhanced production and activation of progelatinase A mediated by membrane-type 1 matrix metalloproteinase in human papillary thyroid carcinomas.
    Nakamura H; Ueno H; Yamashita K; Shimada T; Yamamoto E; Noguchi M; Fujimoto N; Sato H; Seiki M; Okada Y
    Cancer Res; 1999 Jan; 59(2):467-73. PubMed ID: 9927064
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Matrix metalloproteinase-13 expression is associated with bone marrow microinvolvement and prognosis in non-small cell lung cancer.
    Hsu CP; Shen GH; Ko JL
    Lung Cancer; 2006 Jun; 52(3):349-57. PubMed ID: 16569461
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of metalloproteinase-2, metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in transitional cell carcinoma of upper urinary tract: correlation with tumor stage and survival.
    Miyata Y; Kanda S; Nomata K; Hayashida Y; Kanetake H
    Urology; 2004 Mar; 63(3):602-8. PubMed ID: 15028476
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of matrix metalloproteinases 1, 2, 9 and their tissue inhibitors in stage II non-small cell lung cancer: implications for MMP inhibition therapy.
    Pritchard SC; Nicolson MC; Lloret C; McKay JA; Ross VG; Kerr KM; Murray GI; McLeod HL
    Oncol Rep; 2001; 8(2):421-4. PubMed ID: 11182067
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The serum concentration of metalloproteinase 9 and 2 in non-small cell lung cancer patients].
    Kopczyńska E; Dancewicz M; Kowalewski J; Kardymowicz H; Tyrakowski T
    Pol Merkur Lekarski; 2007 Jun; 22(132):539-41. PubMed ID: 17874625
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The combination assay with circulating vascular endothelial growth factor (VEGF)-C, matrix metalloproteinase-9, and VEGF for diagnosing lymph node metastasis in patients with non-small cell lung cancer.
    Tamura M; Oda M; Matsumoto I; Tsunezuka Y; Kawakami K; Ohta Y; Watanabe G
    Ann Surg Oncol; 2004 Oct; 11(10):928-33. PubMed ID: 15383417
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of matrix metalloproteinases 7 and 9 in non-small cell lung cancer. Relation to clinicopathological factors, beta-catenin and prognosis.
    Leinonen T; Pirinen R; Böhm J; Johansson R; Ropponen K; Kosma VM
    Lung Cancer; 2006 Mar; 51(3):313-21. PubMed ID: 16423426
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Significant relationship of matrix metalloproteinase 9 with nuclear grade and prognostic impact of tissue inhibitor of metalloproteinase 2 for incidental clear cell renal cell carcinoma.
    Kawata N; Nagane Y; Hirakata H; Ichinose T; Okada Y; Yamaguchi K; Takahashi S
    Urology; 2007 Jun; 69(6):1049-53. PubMed ID: 17572184
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.